It is an exciting time in cancer drug discovery. Seven in 10 people now survive their cancer five years or more, up from only half in the mid-70s, according to the American Cancer Society’s 2026 Cancer Statistics. New modalities, like radiopharmaceuticals, alongside new drug targets, like KRAS mutations, are resulting in therapies that can be more targeted and […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!